Yahoo
NYSE - Delayed Quote USD

Charles River Laboratories International, Inc. (CRL)

185.00 +2.66 (+1.46%)
At close: June 18 at 4:00:02 PM EDT
Trade CRL on Coinbase
Chart Range Bar
Loading chart for CRL

News headlines Charles River Laboratories (CRL) is gaining attention as Morgan Stanley upgrades its rating to Overweight with a target price of $220, highlighting its potential in the recovering biotech sector. Additionally, CRL is collaborating with Lilly’s TuneLab to enhance AI/ML drug discovery capabilities.

Charles River Laboratories (CRL) is gaining attention as Morgan Stanley upgrades its rating to Overweight with a target price of $220, highlighting its potential in the recovering biotech sector. Additionally, CRL is collaborating with Lilly’s TuneLab to enhance AI/ML drug discovery capabilities.

Updated 50m ago · Powered by Yahoo Scout
  • Previous Close 182.34
  • Open 183.70
  • Bid 185.10 x 30000
  • Ask 200.00 x 40000
  • Day's Range 182.00 - 186.18
  • 52 Week Range 144.26 - 228.88
  • Volume 1,170,070
  • Avg. Volume 865,026
  • Market Cap (intraday) 8.911B
  • Beta (5Y Monthly) 1.45
  • PE Ratio (TTM) --
  • EPS (TTM) -3.71
  • Earnings Date (est.) Aug 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 212.27

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

www.criver.com

18,300

Full Time Employees

December 27

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CRL
7.26%
S&P 500 (^GSPC)
9.57%

1-Year Return

CRL
27.33%
S&P 500 (^GSPC)
25.41%

3-Year Return

CRL
11.90%
S&P 500 (^GSPC)
70.10%

5-Year Return

CRL
47.70%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 995.83M
Earnings 101.7M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
200M
400M
600M
800M
1B

Analyst Insights

View More

Analyst Price Targets

135.00 Low
212.27 Average
185.00 Current
265.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/17/2026
Analyst Morgan Stanley
Rating Action Upgrade
Rating Overweight
Price Action Raises
Price Target 185 -> 220

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    8.91B

  • Enterprise Value

    11.78B

  • Trailing P/E

    --

  • Forward P/E

    16.61

  • PEG Ratio (5yr expected)

    0.12

  • Price/Sales (ttm)

    2.26

  • Price/Book (mrq)

    3.03

  • Enterprise Value/Revenue

    2.92

  • Enterprise Value/EBITDA

    40.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.59%

  • Return on Assets (ttm)

    4.26%

  • Return on Equity (ttm)

    -5.87%

  • Revenue (ttm)

    4.03B

  • Net Income Avi to Common (ttm)

    -184.65M

  • Diluted EPS (ttm)

    -3.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    191.83M

  • Total Debt/Equity (mrq)

    102.55%

  • Levered Free Cash Flow (ttm)

    510.02M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

185.00 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook

    Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

    Rating
    Price Target
  • Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook

    Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

    Rating
    Price Target
  • Charles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook

    Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

    Rating
    Price Target
  • Charles River: Downgrading Moat Rating to None and Decreasing Fair Value Estimate to $135

    Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: